BioLife Solutions, Inc.
BLFS
$20.53
-$1.92-8.53%
| Weiss Ratings | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.65 | |||
| Price History | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -19.33% | |||
| 30-Day Total Return | -22.87% | |||
| 60-Day Total Return | -24.12% | |||
| 90-Day Total Return | -18.98% | |||
| Year to Date Total Return | -21.43% | |||
| 1-Year Total Return | 17.48% | |||
| 2-Year Total Return | 1.78% | |||
| 3-Year Total Return | -15.00% | |||
| 5-Year Total Return | 99.90% | |||
| 52-Week High % Change | -24.05% | |||
| 52-Week Low % Change | 51.21% | |||
| Price | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $29.55 | |||
| 52-Week Low Price | $14.84 | |||
| 52-Week Low Price (Date) | Apr 18, 2024 | |||
| 52-Week High Price (Date) | Jan 30, 2025 | |||
| Valuation | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.05B | |||
| Enterprise Value | 973.55M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.46 | |||
| Earnings Per Share Growth | -70.72% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 13.10 | |||
| Price/Book (Q) | 3.02 | |||
| Enterprise Value/Revenue (TTM) | 11.84 | |||
| Price | $20.57 | |||
| Enterprise Value/EBITDA (TTM) | 810.75 | |||
| Enterprise Value/EBIT | -136.56 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 48.03M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 425 402 1400 | |||
| Address | 3303 Monte Villa Parkway Bothell, WA 98021 | |||
| Website | www.biolifesolutions.com | |||
| Country | United States | |||
| Year Founded | 1987 | |||
| Profitability | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -8.66% | |||
| Profit Margin | -24.53% | |||
| Management Effectiveness | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -1.10% | |||
| Return on Equity | -- | |||
| Income Statement | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 82.25M | |||
| Total Revenue (TTM) | 82.25M | |||
| Revenue Per Share | $1.71 | |||
| Gross Profit (TTM) | 53.67M | |||
| EBITDA (TTM) | 1.20M | |||
| EBIT (TTM) | -7.13M | |||
| Net Income (TTM) | -20.18M | |||
| Net Income Avl. to Common (TTM) | -20.18M | |||
| Total Revenue Growth (Q YOY) | 44.21% | |||
| Earnings Growth (Q YOY) | -85.56% | |||
| EPS Diluted (TTM) | -0.46 | |||
| EPS Diluted Growth (Q YOY) | 176.93% | |||
| Balance Sheet | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 104.58M | |||
| Cash Per Share (Q) | $2.18 | |||
| Total Current Assets (Q) | 148.76M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 348.91M | |||
| Current Ratio (Q) | 4.545 | |||
| Book Value Per Share (Q) | $7.44 | |||
| Total Assets (Q) | 399.49M | |||
| Total Current Liabilities (Q) | 32.73M | |||
| Total Debt (Q) | 30.17M | |||
| Total Liabilities (Q) | 50.58M | |||
| Total Common Equity (Q) | 348.91M | |||
| Cash Flow | BLFS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 58.30M | |||
| Cash from Financing (TTM) | -6.78M | |||
| Net Change in Cash (TTM) | 59.95M | |||
| Levered Free Cash Flow (TTM) | 41.73M | |||
| Cash from Operations (TTM) | 8.43M | |||
